RxDoctor Payments Data

Mustapha Abouda, MD

Family Medicine · Espanola, NMNPI 1477654697

Payments from drug & device makers

$626in general payments, 2019–2025

Across 37 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$262
  • Boehringer Ingelheim$94
  • AstraZeneca$64
  • Amgen$57
  • Sanofi-aventis U.S. LLC$49
  • Lilly USA, LLC$38
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$626100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$626 in reported general payments places this provider in the 75th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$139,436
Medicare patients
213
Services billed
2,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin158$153,012
OzempicSemaglutide105$133,976
FarxigaDapagliflozin Propanediol124$94,544
Tresiba Flextouch U-100Insulin Degludec86$54,100
JanuviaSitagliptin Phosphate43$40,974
Tresiba Flextouch U-200Insulin Degludec20$38,246
TrulicityDulaglutide22$33,178
EliquisApixaban32$26,432
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$11,688
XareltoRivaroxaban21$11,643
TradjentaLinagliptin16$11,357
SymbicortBudesonide/Formoterol Fumarate35$10,393
Atorvastatin Calcium727$7,676
Levemir FlexpenInsulin Detemir17$5,398
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen187$4,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$94$164,369174 claims
Novo NordiskOzempic$262$133,976105 claims
AstraZenecaFarxiga, Symbicort$64$104,937159 claims
Lilly USA, LLCTrulicity$38$33,17822 claims
PfizerEliquis$19$26,43232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Espanola

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →